- Home
- TII vs AVIR Comparison
TII vs AVIR Comparison
Compare TII & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TII
- AVIR
- Stock Information
- Founded
- TII 2012
- AVIR 2012
- Country
- TII Canada
- AVIR United States
- Employees
- TII N/A
- AVIR 56
- Industry
- TII
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- TII
- AVIR Health Care
- Exchange
- TII Nasdaq
- AVIR Nasdaq
- Market Cap
- TII 220.5M
- AVIR 236.7M
- IPO Year
- TII N/A
- AVIR 2020
- Fundamental
- Price
- TII $2.59
- AVIR $3.04
- Analyst Decision
- TII
- AVIR Hold
- Analyst Count
- TII 0
- AVIR 1
- Target Price
- TII N/A
- AVIR $6.00
- AVG Volume (30 Days)
- TII 51.4K
- AVIR 450.0K
- Earning Date
- TII 03-20-2026
- AVIR 11-12-2025
- Dividend Yield
- TII N/A
- AVIR N/A
- EPS Growth
- TII N/A
- AVIR N/A
- EPS
- TII 0.12
- AVIR N/A
- Revenue
- TII $75,461,000.00
- AVIR N/A
- Revenue This Year
- TII N/A
- AVIR N/A
- Revenue Next Year
- TII N/A
- AVIR N/A
- P/E Ratio
- TII $17.41
- AVIR N/A
- Revenue Growth
- TII 54.36
- AVIR N/A
- 52 Week Low
- TII $0.25
- AVIR $2.46
- 52 Week High
- TII $3.39
- AVIR $4.02
- Technical
- Relative Strength Index (RSI)
- TII N/A
- AVIR 45.46
- Support Level
- TII N/A
- AVIR $2.93
- Resistance Level
- TII N/A
- AVIR $3.18
- Average True Range (ATR)
- TII 0.00
- AVIR 0.13
- MACD
- TII 0.00
- AVIR -0.02
- Stochastic Oscillator
- TII 0.00
- AVIR 27.78
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).